Takeaways VUEWAY should help Bracco win share in Canada’s MRI contrast market by offering radiology departments a lower‑gadolinium option that still delivers high‑quality images, which is increa...
Takeaways: Cysklar gives Canada’s small cystinosis community a dedicated, easy‑to‑use cysteamine eye‑drop option for corneal crystals, strengthening Leadiant’s rare‑disease ...
Takeaways: Neffy creates a new, needle‑free niche in Canada’s anaphylaxis market that should boost overall epinephrine use and take share from traditional auto‑injectors, especially among ...
Takeaways: AstraZeneca deepens its Saphnelo franchise in Canada by adding a self‑administered SC autoinjector on top of IV, improving convenience and persistency in a chronic, mostly f...
Takeaways: Empaveli’s C3G/IC‑MPGN nod makes Sobi/Apellis the first movers in complement‑mediated kidney disease in Canada, turning a ~700‑patient ultra‑rare population into a high‑value, pr...
Takeaways: Apotex’s Denoza biosimilar gives Canada a home‑grown denosumab option, intensifying price and tender pressure on Amgen’s Prolia in a market with 2.3M osteoporosis ...
Takeaways: Health Canada’s CTA clearance positions Affinia among the first wave of next‑gen cardiac gene therapy players, using a bespoke AAV capsid to go after genetically defined BAG...
Takeaways: CLOBIVIS modestly strengthens Apotex’s position in Canada’s post‑cataract segment and helps it move up the value chain in eye care beyond pure generics. In marke...
